Asklepios BioPharmaceutical, a gene therapy company, announced the hiring of Tim Kelly as president of manufacturing. Kelly’s role will see him take responsibility for the clinical- and commercial-scale manufacture of adeno-associated viral (AAV) vectors.
Prior to joining AskBio, Kelly had worked as CEO of KBI Biopharma, a contract services organization that provides drug development and biomanufacturing services.
With a growing pipeline of AAV gene therapies, AskBio has decided to invest in its own manufacturing capabilities, which Kelly will take the lead on.
AskBio is currently taking gene therapies for Pompe disease and congestive heart failure through the clinic.